Citations

Clear

1053 citation(s) found for "Andre, F".

Reading Performance and Eye Movement Patterns in Glaucoma
Ikeda, Mariana Chiba , Messias, André M V, Hamada, Koiti Uchida, Bando, André Hiroshi, Nakamura, Vinícius P L, Gracitelli, Carolina P B, Chiba Ikeda, Mariana , Messias, André Marcio Vieira , Teixeira, Sérgio Henrique , Nakamura, Vinícius Pereira Leite, Prata, Tiago S. , Tatham, Andrew J. , Paranhos, Augusto , Gracitelli, Carolina P B

Mayo Clinic

Journal of Glaucoma | June 23, 2026 | Volume: 35 | Issue: 7 | Pages: 501-507

10.1097/ijg.0000000000002727 | PMID 42335967 Get It

Précis: Glaucoma patients of similar age and educational level, compared with healthy individuals, exhibit a greater number of saccades and fixations during eye-tracking-aloud reading, resulting in reduced reading speed. Purpose: To evaluate reading performance in patients with glaucoma compared with controls using an eye tracker and to explore the potential confounding effects of patients’ contrast sensitivity and cognition. Materials and Methods: A cross-sectional study was conducted with 111 participants (57 with glaucoma and 54 controls) with a best-corrected visual acuity of ≥0.5 logMAR. Cognition was assessed using the Montreal Cognitive Assessment, and contrast sensitivity was measured with the Freiburg Visual Acuity and Contrast Test. A reading performance evaluation was conducted using the Minnesota Low Vision Reading Test displayed on slides on a computer screen. Reading speed was calculated in words per minute, and an eye tracker was used to analyze saccade and fixation patterns during the reading task. Results: Mean age was 61.8 (±11.6) and 66.5 (±13.7) in the glaucoma and control groups, respectively ( P =0.05). Best-corrected visual acuity was 0.18 (±0.16) and 0.04 (±0.10) logMAR in the glaucoma and control groups, respectively ( P <0.001). Montreal Cognitive Assessment score was 21.8 (±3.5) in the glaucoma and 21.4 (±4.0) in the control group ( P =0.566). A total of 26% of the glaucoma group and 33% of the control group had at least a primary education. Controls read faster and showed fewer saccades and fixations than patients with glaucoma ( P <0.05) across all 5 slides. Conclusions: Patients with glaucoma exhibit poorer reading performance, as evidenced by eye-tracking data, compared with controls of similar age, cognitive function, and educational level.
Factors Associated With Alcohol Intake in Patients With Newly Diagnosed Breast Cancer
Rajput, Sanjna , Vierkant, Robert A., Larson, Nicole L. , Stan, Daniela L., Mussallem, Dawn M. , D’Andre, Stacy D. , Couch, F, Olson, Janet E., O’Sullivan, Ciara C., Ruddy, Kathryn J. , Vierkant, Robert A., Couch, Fergus J. , Olson, Janet E. , O’Sullivan, Ciara C.

Mayo Clinic

Cancer Medicine | June 17, 2026 | Volume: 15 | Issue: 6 | Pages: No page available

10.1002/cam4.72031 | PMID 42304465 Get It

ABSTRACT Background Alcohol intake is a modifiable risk factor for breast cancer, yet patterns of alcohol intake in women with breast cancer remain underexplored. This study evaluates demographic and clinical predictors of alcohol intake in patients with breast cancer. Methods Patients at Mayo Clinic Rochester diagnosed with breast cancer (Stage 0–3) between July 2014 to March 2022 were surveyed about their average alcohol intake over the 10 years prior to their diagnosis. Alcohol intake was categorized as < 1, 1–4, 5–14, and ≥ 15 drinks per week. Demographic, behavioral, and clinical data were analyzed using univariate Fisher exact tests and multivariate multinomial logistic regression. Results Of 2030 participants (mean age at diagnosis: 59 years; 99.3% female; 95.9% White), 29% consumed < 1 drink/week, 48% reported 1–4 drinks/week, 20% consumed 5–14 drinks/week, and 3% reported ≥ 15 drinks/week. Older age at diagnosis (≥ 60 years), non‐White race, financial difficulty, and never smoking were associated with less alcohol intake. Patients who reported higher levels of mild–moderate intensity exercise reported more alcohol intake. Tumor stage, tumor receptors, and BRCA mutation status were not associated with alcohol intake. PROMIS‐10 physical health scores correlated with alcohol intake in univariate but not multivariate models. Conclusion Alcohol intake is more common prior to a breast cancer diagnosis for patients who are younger, White, financially secure, exercising, and smoking. These findings may inform alcohol intake‐related breast cancer prevention efforts and highlight patient subgroups who could benefit from targeted counseling at the time of diagnosis.
An Open-label Study Evaluating the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Tanruprubart Single Dose in Participants From North America and Europe With Guillain-Barré Syndrome (P3-19.004)
Ladha, Shafeeq, Grover, Kavita, Morrison, Glenn, Lin, Ping, Kroon, Henk‐André, Allen, Jeffrey, Ladha, Shafeeq , Mustafa, Rafid , Grover, Kavita Mohindra , Lin, Ping , Allen, Jeffrey

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000216099 Get It

Anti-IgLON-5 Disease with Myasthenia Gravis-like Symptoms and Abnormal Single Fiber EMG: Is There Pathology at the Neuromuscular Junction? (P1-1.006)
Montecino, Dominique, Granger, Andre

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217188 Get It

Novel Compound Heterozygous SPG7 Mutation Mimicking Amyotrophic Lateral Sclerosis (P5-9.017)
Doward, Matthew, Granger, Andre

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215000 Get It

Clinical impact of R0 resection after chemotherapy in initially unresectable metastatic colorectal cancer: A pooled analysis of the ARCAD database.
Ando, Koji, Misumi, Toshihiro, Bando, Hideaki, Nishikawa, Tomomi, Maughan, Tim, Díaz-Rubio, E E, Sugihara, Kenichi , Maehara, Yoshihiko, Andre, Thierry, Shi, Qian, Gramont, Aimery De, Yoshino, Takayuki, Oki, Eiji, Ando, Koji , Misumi, Toshihiro , Bando, Hideaki , Nishikawa, Tomomi, Maehara, Yoshihiko , André, Thierry , Shi, Qian , Gramont, Aimery de , Yoshino, Takayuki , Oki, Eiji

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e15557 Get It

e15557 Background: In metastatic colorectal cancer (mCRC), systemic chemotherapy can enable conversion surgery in a subset of patients with initially unresectable disease. Although R0 resection considered a key determinant of long-term survival, its clinical impact across heterogeneous trial populations and treatment strategies remains insufficiently defined. We aimed to clarify the survival benefit of R0 resection after first-line chemotherapy using large-scale individual patient data. Methods: Using the ARCAD database, which comprises 67 randomized clinical trials and approximately 47,000 patients, we conducted a pooled analysis of individual patient data from six first-line randomized clinical trials (COIN, COIN-B, 03-TTD-01, ATOM, SOFT and PARADIGM) for which data on R0 resection were available. Patients with initially unresectable mCRC and available surgical data were categorized into three groups: R0 resection, non-R0 resection, and no surgery. All R0 cases were included, comprising liver-only, lung-only, combined liver and lung metastases, and peritoneal dissemination or other metastatic sites. Overall survival (OS) and progression-free survival (PFS) were evaluated using multivariable Cox proportional hazards models adjusted for age, sex, and performance status. Pre-specified subgroup analyses examined the consistency of outcomes according to tumor response, metastatic site, primary tumor sidedness, RAS status, and targeted therapy class. Results: Among 4,445 eligible patients, 263 underwent R0 , 233 underwent non-R0 resection, and 3,949 received no surgical intervention. The R0 resection group comprised patients with liver-only metastases (n = 176), lung-only metastases (n = 23), and combined liver and lung metastases (n = 27). R0 resection was associated with significantly improved OS and PFS compared with both non-R0 resection and no surgery. These survival benefits were consistently observed across key clinical subgroups, including patients achieving complete or partial response to chemotherapy, those with liver or lung metastases, left- and right-sided primary tumors, and both RAS wild-type and mutant disease. Importantly, the benefit of R0 resection was maintained irrespective of anti-EGFR– or anti-VEGF–based first-line therapy. Conclusions: R0 resection following systemic chemotherapy is strongly associated with durable survival benefits in patients with initially unresectable mCRC across diverse clinical settings. These findings support the pivotal role of conversion strategies and highlight the importance of multidisciplinary evaluation to identify appropriate candidates for curative-intent resection.
Impact of outpatient CAR T-cell therapy administration on healthcare utilization in patients with hematologic malignancies.
Bowen, Susanna Goggans, Abdallah, Nadine, Corraes, Andre De Menezes Silva, Oyarzabal, Beatriz, Harmsen, W.L., LUNDE, JULIANNE, Coffey, J C, Haugen, Kelsey L., Rosenthal, Allison Claire, Iqbal, Madiha, Kapoor, Prashant , Bennani, Nabila Nora, Johnston, Patrick B., Ansell, Stephen M., Kharfan-Dabaja, Mohamed, Haddad, Tufia C. , Lin, Yi, Paludo, Jonas, Abdallah, Nadine , Pritchett, Joshua C. , Corraes, Andre De Menezes Silva , Oyarzabal, Beatriz A., Lunde, Julianne J. , Haugen, Kelsey, Rosenthal, Allison , Iqbal, Madiha , Alkhateeb, Hassan B. , Johnston, Patrick B. , Ansell, Stephen M. , Kharfan‐Dabaja, Mohamed A. , Paludo, Jonas

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 1503-1503

10.1200/jco.2026.44.16_suppl.1503 Get It

1503 Background: CAR T-cell therapy has revolutionized treatment outcomes in hematological malignancies, but has traditionally required inpatient post-infusion monitoring, which is associated with significant cost and time toxicity. Outpatient CAR T infusion and monitoring has been the standard approach at Mayo Clinic site in Rochester, MN, with demonstrated feasibility and safety (Bansal et al., ASCO 2023). We present data comparing healthcare utilization between CAR T recipients who underwent outpatient remote monitoring and those with traditional inpatient monitoring. Methods: Electronic medical records were retrospectively analyzed for 293 patients who received CAR T-cell therapy for a hematological malignancy at any of the 3 Mayo Clinic sites (MN, AZ, FL) between 2020 and 2024 . Healthcare utilization was compared between patients who received outpatient CAR T with remote patient monitoring in Rochester, MN (N = 125) and those who received inpatient CAR T in the Arizona (n = 90) and Florida (n = 78) sites. Per protocol, patients in the inpatient group underwent mandatory inpatient monitoring for 7 days, with extension per provider discretion. Data was analyzed through Chi-Square and Wilcoxon tests. P values < 0.05 were considered statistically significant. Results: There was no significant difference in baseline sex, age, ethnicity, LDH, platelets, or neutrophils among the 293 patients. Diagnoses included lymphoma (n = 175), multiple myeloma (n = 106), and B-ALL (n = 12). The most common CAR T-cell products used were axicabtagene ciloleucel (n = 138) idecabtagene vicleucel (n = 56), and ciltacabtagene autoleucel (n = 50). Median hospital days were lower in the outpatient group vs the inpatient group at 30 days (4.4 vs 13.3, P < 0.001) and 90 days (4.6 vs 13.6, P < 0.001). ICU admission occurred in 1 outpatient patient ( < 1%) vs 18 inpatient patients (11%) in the first 30 days (P < 0.001). In the first 30 days, 22% of patients in the outpatient group did not require hospitalization, while 56%, 15%, and 6% required 1, 2, and 3 hospitalizations, respectively. Similarly, only 11 (8.8%) patients in the outpatient group had ≥1 ED visit in the first 30 days compared with 32 (20%) pts in the inpatient group (P = 0.009). At 30 days, there was no difference in patient portal use, with 58% of patients using the portal at least once and a median of 1 message in both groups. Within the first 30 days, 53% and 2% of patients in the outpatient group required 1 and 2 outpatient visits, respectively, vs 29% and 2% in the inpatient group (P < 0.001). There was no difference in 30-day mortality (1.6% outpatient vs 2.4% in inpatient) between the 2 groups (P = 1.00) Conclusions: Outpatient CAR T-cell therapy monitoring was associated with significantly fewer hospital days without increased ED visits, ICU stays, portal use, or 30-day mortality. This demonstrates lower healthcare utilization for outpatient CAR-T therapy.
Predictors of hospital length of stay, discharge disposition, and readmission after craniopharyngioma surgery: a multicenter study from the RAPID database
Tenhoeve, Samuel A. , Tang, Anthony , Orton, Cody , Gautam, Diwas, Abdul-Rahman, Nana-Hawwa, Silverstein, Julie M., Kim, Albert H., Evans, James J., Barkhoudarian, Garni, Fernandez-Miranda, Juan C., Pacione, Donato , Kim, Won, Bergsneider, Marvin, Zada, Gabriel, Kshettry, Varun R., Wu, Kyle C., Benjamin, Carolina G., Gompel, Jamie J. Van, Catalino, Michael P., Mamelak, Adam N., Zwagerman, Nathan T., Cheok, Stephanie K., Little, Andrew S., Zenonos, Georgios A., Karsy, Michael, Morshed, Ramin A., Blackburn, Spiros L., Mukherjee, Debraj, Beer-Furlan, Andre, Couldwell, William T., Gardner, Paul A., Rennert, Robert C., Karsy, Michael , Mukherjee, Debraj , Barkhoudarian, Garni , Van Gompel, Jamie, Palit, Sandhya R. , Mukherjee, Debraj , Karsy, Michael , Gautam, Diwas , Abdul‐Rahman, Nana‐Hawwa , Silverstein, Julie , Kim, Albert H , Evans, James J., Fernandez‐Miranda, Juan C. , Bergsneider, Marvin , Chicoine, Michael , Zada, Gabriel , Kshettry, Varun R. , Gompel, Jamie J. Van , Catalino, Michael Paul, Mamelak, Adam N, Zwagerman, Nathan T. , Cheok, Stephanie , Little, Andrew S. , Zenonos, Georgios A. , Morshed, Ramin A. , Blackburn, Spiros L., Beer‐Furlan, André , Couldwell, William T. , Gardner, Paul A. , Rennert, Robert C

Mayo Clinic

Neurosurgical Focus | May 27, 2026 | Volume: 60 | Issue: 6 | Pages: E6

10.3171/2026.2.focus251047 | PMID 42224727 Get It

OBJECTIVE Craniopharyngiomas are benign intracranial tumors that can be difficult to manage operatively and often result in postoperative complications and prolonged recovery. Understanding the factors that influence length of stay (LOS), discharge disposition, and readmission can guide perioperative planning and patient counseling. The authors examined the clinical, radiographic, and surgical predictors of extended LOS (eLOS), nonhome discharge, 90-day readmission, and hospitalization ratio (HR) after craniopharyngioma resection using a large, multicenter cohort. METHODS A retrospective analysis was conducted using the Registry of Adenomas of the Pituitary and Related Disorders database, encompassing 469 patients who underwent craniopharyngioma resection at 14 US academic centers from 2011 to 2025. Patients were stratified by 4 outcomes: eLOS (> 75th percentile), discharge to home versus skilled nursing facility/rehabilitation, 90-day hospital readmission, and hospitalization ratio (i.e., integration of initial and readmission LOS). Multivariable logistic regression models identified independent predictors for each outcome among patient and surgical variables. RESULTS An eLOS (> 10 days) was independently associated with preoperative memory loss (OR 3.75, 95% CI 1.95–7.21), gait imbalance (OR 5.90, 95% CI 1.53–22.70), and postoperative complications (OR 4.07, 95% CI 2.34–7.06). The use of a nasoseptal flap was protective against an eLOS (OR 0.52, 95% CI 0.28–0.93). Discharge to home was predicted by an endoscopic approach (OR 3.87, 95% CI 1.78–8.44) and postoperative intact thirst (OR 2.22, 95% CI 1.05–4.66) and negatively predicted by preoperative diabetes mellitus (OR 0.21, 95% CI 0.09–0.50), LOS (OR 0.87, 95% CI 0.84–0.91), and postoperative cognitive dysfunction (OR 0.30, 95% CI 0.13–0.72). Among 385 patients with follow-up data, a 90-day readmission was independently associated with postoperative complications (OR 5.62, 95% CI 3.12–10.13), preexisting coronary artery disease (OR 4.30, 95% CI 1.46–12.69), and postoperative cognitive dysfunction (OR 3.33, 95% CI 1.76–6.44). A higher HR was associated with diabetes mellitus (unstandardized B 0.059, 95% CI 0.010–0.108, p = 0.02), postoperative complications (unstandardized B 0.054, 95% CI 0.021–0.086, p = 0.001), and postoperative cognitive dysfunction (unstandardized B 0.049, 95% CI 0.006–0.092, p = 0.02). Tumor pathologic subtype and size, prior treatment, extent of resection, and surgeon experience were not directly predictive of outcomes. CONCLUSIONS Cognitive and functional status, systemic comorbidities, and postoperative complications, in addition to surgical approach, are important predictors of the early clinical course after craniopharyngioma surgery. Early identification of high-risk patients may help to guide treatment decisions, improve discharge planning, and reduce healthcare utilization.
The landscape of antibody production systems: recombinant expression for research, diagnostics and therapy
Al-Halabi-Frenzel, Laila, Demiral, Seyhan, Frenzel, André , Gnann, Dianne Celine , Keitel, Martha Charlotte-Elisabeth, Lehmler, Nina, Rauls, Justus, Schirrmann, Thomas , Stańczyk, Piotr Grzegorz, Terbrack, Jan, Westerhoff, Sofie, Dübel, Stefan, Hust, Michael, Dübel, Stefan , Wenzel, Esther Veronika , Mukherjee, Tarushyam , Steinke, Stephan , Schubert, Maren , Hust, Michael , Bertoglio, Federico

Mayo Clinic

Frontiers in Bioengineering and Biotechnology | May 20, 2026 | Volume: 14 | Issue: No issue available | Pages: No page available

10.3389/fbioe.2026.1765764 | PMID 42245239 Get It

Over the past three decades, the emergence of recombinant antibodies has positioned them as the fastest-growing class of therapeutic proteins and as well as crucial reagents for both diagnostics and specific research applications. The industrial production of most therapeutic antibodies currently relies on mammalian cell lines, primarily Chinese Hamster Ovary (CHO) cells, which remain the gold standard in biopharmaceutical manufacturing due to their exceptionally high production yields, robustness, regulatory acceptance, and consistent product quality. Nevertheless, new approaches using specifically adapted expression systems are emerging. These new host organisms enable the production of antibodies with posttranslational modifications that closely resemble those found in the human system, without the need for animal-derived source materials. For diagnostic and research purposes, a broad range of production systems has been developed. These include Gram-negative and Gram-positive bacteria, yeasts, filamentous fungi, insect cell lines, and transgenic plants. Additionally, smaller single domain antibodies and bispecific fragments that do not require glycosylation can be successfully produced in bacteria for therapeutic applications. Some of these molecules have already been approved by regulatory authorities in the European Union and the United States, and several more are currently in clinical trials. This review therefore focuses on the broad and evolving landscape of recombinant antibody production systems and their applicability across various fields.